Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.


Fulminant Myocarditis: A Review of the Current Literature


US Cardiology Review 2018;12(1):13–6.

Influence of Race in the Association of Diabetes and Heart Failure


US Cardiology Review 2018;12(1):17–21.

Impact of Atrial Septal Defect on Hemodynamics


US Cardiology Review 2017;11(2):72–4.

New Drugs for the Treatment of Heart Failure


US Cardiology Review 2017;11(2):62–6.